Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,goodWill,treasuryStock,cash,totalCurrentLiabilities,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,longTermDebt,inventory,accountsPayable,otherAssets,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,changeToInventory,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,currency,esgPopulated,tradeable,market,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,marketState,shortName,exchange,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,exchangeDataDelayedBy,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,priceHint,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Oct 12, 2017) 4","Short Ratio (Oct 12, 2017) 4","Short % of Float (Oct 12, 2017) 4","Short % of Shares Outstanding (Oct 12, 2017) 4","Shares Short (prior month Sep 14, 2017) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry
t0,EVARF,-18837000.0,27950800,1333000,,-8597000,,-7692000,2203000,-607000,-4143000,-4143000,,-720000,,,,-905000,2400000,6543000,3007000,-4454000,,-7692000,-7692000,18148000.0,68710000.0,53794000.0,13973000.0,94000.0,67767000.0,280000.0,-257818000.0,13430000.0,14662000.0,202801000.0,20797000.0,10072000.0,4267000.0,202801000.0,1373000.0,33584000.0,5393000.0,30292000.0,6877000.0,3301000.0,,-2332000,9000,10008000,14594000,5000000,10940000,-874000,-2789000,86000,1000,1891000,835000,-414000,4018000,-5000,23512000.0,en-US,US,EQUITY,False,Delayed Quote,0.0,0.0025 - 0.0025,0.0025,0.0,0.0,0,0,finmb_20947639,Other OTC,"Lombard Medical, Inc.",USD,43618,92292,0.00049999985,0.24999991,0.002 - 0.075,-0.072500005,-0.9666667,0.002,0.075,USD,False,False,us_market,0.0025,1630002149,0.0,0.0037,0.0025,0.0025,462000,REGULAR,LOMBARD MED INC,PNK,1535128200,1535992200,-1.539,-1.02,0,0.5,0.006325,-0.003825,-0.60474306,0.016279085,-0.013779085,-0.84642875,48103,-0.0024509805,0.005,15,America/New_York,EDT,-14400000,4,6.58,,,0.075,0.002,0.0063,0.0163,43.62k,92.29k,27.95M,,19.59M,0.00%,6.58%,34.67k,0.31,0.35%,0.12%,24.71k,,,,,,0.00%,,,,,"Dec 30, 2016","Dec 30, 2016",-255.03%,-209.72%,-20.78%,-108.73%,12.17M,0.60,-18.50%,1.14M,-24.22M,-31.04M,-1.5390,,20.8M,0.74,34.56M,247.33,3.33,0.50,-25.2M,-17.21M,Value,OX11 7HJ,Healthcare,113,"Lombard Medical, Inc., a medical technology company, develops, manufactures, and markets endovascular stent-grafts for the repair of aortic aneurysms in the United States, the United Kingdom, Germany, Japan, and internationally. The company's principal product is Aorfix, which is an endovascular stent-graft for the treatment of abdominal aortic aneurysms (AAAs) with angulation at the neck of the aneurysm of up to 90 degrees. Its products also include Altura endovascular stent graft system for the treatment of standard AAA anatomies; Aorflex delivery system for accurate placement of Aorfix in the abdominal aorta; and IntelliFlex LP delivery system that enhances the precision and control of Aorfix deployment and placement. Lombard Medical, Inc. sells its products directly through its direct sales force and distributors to state-or-government-owned hospitals. The company was founded in 2000 and is headquartered in Didcot, the United Kingdom.",Didcot,44 12 3575 0800,1483142400,United Kingdom,http://www.lombardmedical.com,86400,4 Trident Park,44 12 3575 0879,Medical Devices
t-1,EVARF,-18958000.0,27950800,1739000,,-7583000,,-7422000,5376000,350000,-6765000,-6765000,,-547000,,,,-161000,3044000,9809000,2694000,-818000,,-7422000,-7422000,20951000.0,63853000.0,46479000.0,17664000.0,87000.0,64143000.0,199000.0,-250292000.0,12271000.0,15671000.0,203904000.0,9857000.0,10785000.0,2642000.0,203904000.0,2001000.0,25349000.0,6550000.0,23423000.0,8942000.0,5406000.0,171000.0,960000,100000,2399000,2004000,5000000,-3122000,-374000,-4852000,19000,7000,-579000,780000,-395000,757000,-11000,14564000.0,en-US,US,EQUITY,False,Delayed Quote,0.0,0.0025 - 0.0025,0.0025,0.0,0.0,0,0,finmb_20947639,Other OTC,"Lombard Medical, Inc.",USD,43618,92292,0.00049999985,0.24999991,0.002 - 0.075,-0.072500005,-0.9666667,0.002,0.075,USD,False,False,us_market,0.0025,1630002149,0.0,0.0037,0.0025,0.0025,462000,REGULAR,LOMBARD MED INC,PNK,1535128200,1535992200,-1.539,-1.02,0,0.5,0.006325,-0.003825,-0.60474306,0.016279085,-0.013779085,-0.84642875,48103,-0.0024509805,0.005,15,America/New_York,EDT,-14400000,4,6.58,,,0.075,0.002,0.0063,0.0163,43.62k,92.29k,27.95M,,19.59M,0.00%,6.58%,34.67k,0.31,0.35%,0.12%,24.71k,,,,,,0.00%,,,,,"Dec 30, 2016","Dec 30, 2016",-255.03%,-209.72%,-20.78%,-108.73%,12.17M,0.60,-18.50%,1.14M,-24.22M,-31.04M,-1.5390,,20.8M,0.74,34.56M,247.33,3.33,0.50,-25.2M,-17.21M,Value,OX11 7HJ,Healthcare,113,"Lombard Medical, Inc., a medical technology company, develops, manufactures, and markets endovascular stent-grafts for the repair of aortic aneurysms in the United States, the United Kingdom, Germany, Japan, and internationally. The company's principal product is Aorfix, which is an endovascular stent-graft for the treatment of abdominal aortic aneurysms (AAAs) with angulation at the neck of the aneurysm of up to 90 degrees. Its products also include Altura endovascular stent graft system for the treatment of standard AAA anatomies; Aorflex delivery system for accurate placement of Aorfix in the abdominal aorta; and IntelliFlex LP delivery system that enhances the precision and control of Aorfix deployment and placement. Lombard Medical, Inc. sells its products directly through its direct sales force and distributors to state-or-government-owned hospitals. The company was founded in 2000 and is headquartered in Didcot, the United Kingdom.",Didcot,44 12 3575 0800,1483142400,United Kingdom,http://www.lombardmedical.com,86400,4 Trident Park,44 12 3575 0879,Medical Devices
t-2,EVARF,-11426000.0,27950800,2291000,,-8525000,,-8315000,5417000,415000,-7293000,-7293000,,-538000,,,,-210000,3803000,11096000,3388000,-1232000,,-8315000,-8315000,21219000.0,63853000.0,42790000.0,25549000.0,,68339000.0,199000.0,-243107000.0,11982000.0,15756000.0,204604000.0,12979000.0,8431000.0,1047000.0,204604000.0,2429000.0,28764000.0,7241000.0,22377000.0,8544000.0,7384000.0,171000.0,218000,-7000,2399000,-396000,5000000,-9385000,16000,-9000000,796000,19000,-1092000,-1647000,-396000,1289000,-26000,20333000.0,en-US,US,EQUITY,False,Delayed Quote,0.0,0.0025 - 0.0025,0.0025,0.0,0.0,0,0,finmb_20947639,Other OTC,"Lombard Medical, Inc.",USD,43618,92292,0.00049999985,0.24999991,0.002 - 0.075,-0.072500005,-0.9666667,0.002,0.075,USD,False,False,us_market,0.0025,1630002149,0.0,0.0037,0.0025,0.0025,462000,REGULAR,LOMBARD MED INC,PNK,1535128200,1535992200,-1.539,-1.02,0,0.5,0.006325,-0.003825,-0.60474306,0.016279085,-0.013779085,-0.84642875,48103,-0.0024509805,0.005,15,America/New_York,EDT,-14400000,4,6.58,,,0.075,0.002,0.0063,0.0163,43.62k,92.29k,27.95M,,19.59M,0.00%,6.58%,34.67k,0.31,0.35%,0.12%,24.71k,,,,,,0.00%,,,,,"Dec 30, 2016","Dec 30, 2016",-255.03%,-209.72%,-20.78%,-108.73%,12.17M,0.60,-18.50%,1.14M,-24.22M,-31.04M,-1.5390,,20.8M,0.74,34.56M,247.33,3.33,0.50,-25.2M,-17.21M,Value,OX11 7HJ,Healthcare,113,"Lombard Medical, Inc., a medical technology company, develops, manufactures, and markets endovascular stent-grafts for the repair of aortic aneurysms in the United States, the United Kingdom, Germany, Japan, and internationally. The company's principal product is Aorfix, which is an endovascular stent-graft for the treatment of abdominal aortic aneurysms (AAAs) with angulation at the neck of the aneurysm of up to 90 degrees. Its products also include Altura endovascular stent graft system for the treatment of standard AAA anatomies; Aorflex delivery system for accurate placement of Aorfix in the abdominal aorta; and IntelliFlex LP delivery system that enhances the precision and control of Aorfix deployment and placement. Lombard Medical, Inc. sells its products directly through its direct sales force and distributors to state-or-government-owned hospitals. The company was founded in 2000 and is headquartered in Didcot, the United Kingdom.",Didcot,44 12 3575 0800,1483142400,United Kingdom,http://www.lombardmedical.com,86400,4 Trident Park,44 12 3575 0879,Medical Devices
t-3,EVARF,-2672000.0,27950800,2306000,,-7811000,,-7606000,5998000,984000,-7320000,-7320000,,-548000,,,,-205000,2922000,10242000,1938000,-491000,,-7606000,-7606000,21552000.0,63853000.0,41998000.0,34848000.0,113000.0,76846000.0,199000.0,-235050000.0,11274000.0,15968000.0,205846000.0,22364000.0,7456000.0,,205846000.0,2860000.0,36290000.0,5865000.0,23268000.0,8061000.0,4670000.0,176000.0,-664000,-196000,2399000,-395000,5000000,-9968000,-821000,-8554000,400000,27000,-1701000,34000,-395000,734000,-223000,28834000.0,en-US,US,EQUITY,False,Delayed Quote,0.0,0.0025 - 0.0025,0.0025,0.0,0.0,0,0,finmb_20947639,Other OTC,"Lombard Medical, Inc.",USD,43618,92292,0.00049999985,0.24999991,0.002 - 0.075,-0.072500005,-0.9666667,0.002,0.075,USD,False,False,us_market,0.0025,1630002149,0.0,0.0037,0.0025,0.0025,462000,REGULAR,LOMBARD MED INC,PNK,1535128200,1535992200,-1.539,-1.02,0,0.5,0.006325,-0.003825,-0.60474306,0.016279085,-0.013779085,-0.84642875,48103,-0.0024509805,0.005,15,America/New_York,EDT,-14400000,4,6.58,,,0.075,0.002,0.0063,0.0163,43.62k,92.29k,27.95M,,19.59M,0.00%,6.58%,34.67k,0.31,0.35%,0.12%,24.71k,,,,,,0.00%,,,,,"Dec 30, 2016","Dec 30, 2016",-255.03%,-209.72%,-20.78%,-108.73%,12.17M,0.60,-18.50%,1.14M,-24.22M,-31.04M,-1.5390,,20.8M,0.74,34.56M,247.33,3.33,0.50,-25.2M,-17.21M,Value,OX11 7HJ,Healthcare,113,"Lombard Medical, Inc., a medical technology company, develops, manufactures, and markets endovascular stent-grafts for the repair of aortic aneurysms in the United States, the United Kingdom, Germany, Japan, and internationally. The company's principal product is Aorfix, which is an endovascular stent-graft for the treatment of abdominal aortic aneurysms (AAAs) with angulation at the neck of the aneurysm of up to 90 degrees. Its products also include Altura endovascular stent graft system for the treatment of standard AAA anatomies; Aorflex delivery system for accurate placement of Aorfix in the abdominal aorta; and IntelliFlex LP delivery system that enhances the precision and control of Aorfix deployment and placement. Lombard Medical, Inc. sells its products directly through its direct sales force and distributors to state-or-government-owned hospitals. The company was founded in 2000 and is headquartered in Didcot, the United Kingdom.",Didcot,44 12 3575 0800,1483142400,United Kingdom,http://www.lombardmedical.com,86400,4 Trident Park,44 12 3575 0879,Medical Devices
